



RECEIVED

AUG 09 2002

#3 1653

TECH CENTER 1600/2900

PATENT
Attorney Docket No. P03660US7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: David R. Hathaway
SERIAL NO: 10/091,258
FILED: March 5, 2002
TITLE: COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE

Group Art Unit: 1653
Examiner:
Confirmation No: 8234

**INFORMATION DISCLOSURE STATEMENT
FILED WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement, except those identified above.

CERTIFICATE OF MAILING


I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 1st day of Aug., 2002.


Edmund J. Sease

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

Respectfully submitted,



Edmund J. Sease, Reg. No. 24,741
McKEE, VOORHEES & SEASE, P.L.C.
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

- rl -

Attorneys of Record

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/091,258
Filing Date	March 5, 2002
First Named Inventor	David R. Hathaway
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	P03660US7

RECEIVED
AUG 09 2002
CENTER 1600/2900

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Form PTO/SB/08A (08-00)
U.S. Patent and Trademark Office

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/091,258
Filing Date	March 5, 2002
First Named Inventor	David R. Hathaway
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	P03660US7

RECEIVED
AUG 09 2002
TECH CENTER 1600/2000

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
-	9	APSTEIN, "Glucose-Insulin-Potassium for Acute Myocardial Infarction; Remarkable Results From a New Prospective, Randomized Trial," CIRCULATION, Vol. 98, 24 November 1998, pp. 2223-2226; XP000960510 (no copy)	
-	10	JEFFREY I. WEITZ, JOHN BYRNE, G. PATRICK CLAGETT, MICHAEL E. FARKOUH, JOHN M. PORTER, DAVID L. SACKETT, D. EUGENE STRANDNESS, JR., LLOYD M. TAYLOR; "Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review"; American Heart Association; 1996, pp. 1-43; Dallas, TX.	
-	11	SIMON GREEN; "Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle"; Journal of Vascular Surgery; May 2001, Vol. 33, No. 5, pp. 1-2, Mosby	
-	12	MUREDACH P. REILLY and EMILE R. MOHLER III; "Cilostazol: Treatment of Intermittent Claudication"; The Annals of Pharmacotherapy; 2001 January, Vol. 35, pp. 48-56;	
-	13	CARLOS IRIBARREN, ANDREW J. KARTER, ALAN S. GO, ASSIAMIRA FERRARA, JENNIFER Y. LIU, STEPHEN SIDNEY AND JOSEPH V. SELBY; "Glycemic Control and Heart Failure Among Adult Patients With Diabetes"; American Heart Association; 2001, pp. 2668-2673; American Heart Association, Inc.	
-	14	HARI K. BHAT, WILLIAM R. HIATT, CHARLES L. HOPPEL, ERIC P. BRASS; "Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease"; American Heart Association, Inc., 1999, pp. 807-812; American Heart Association, Inc.	
-	15	ROBERT D. ABBOTT, RICHARD P. DONAHUE, WILLIAM B. KANNEL, PETER W.F. WILSON; "the Impact of Diabetes on Survival Following Myocardial Infarction in Man vs. Woman"; JAMA, December 16, 1988, Vol. 260, No. 23, pp. 3456-3460; National Heart, Lung and Blood Institute, Bethesda, MD	
-	16	FREDERICK N. BRAND, ROBERT D. ABBOTT, AND WILLIAM B. KANNEL; "Diabetes, Intermittent Claudication, and Risk of Cardiovascular Events"; July 1988; Diabetes, Vol. 38, pp. 504-509; National Heart, Lung and Blood Institute, Bethesda, Maryland	
-	17	R. STUART GRAY, RICHARD R. FABSITZ, LINDA D. COWAN, ELISA T. LEE, BARBARA V. HOWARD AND PETER J. SAVAGE; "Risk Factor Clustering in the Insulin Resistance Syndrome"; American Journal of Epidemiology; 1998; Vol. 148, No. 9, pp. 869-878, The Johns Hopkins University School of Hygiene and Public Health.	
-	18	DAVID L. DAWSON, BRUCE S. CUTLER, WILLIAM R. HIATT, ROBERT W. HOBSON II, JOHN D. MARTIN, ENOCH B. BORTEY, WILLIAM P. FORBERS, AND D. EUGENE STRANDNESS, JR.; "A Comparison of Cilostazol and Pentoxifylline for Treating Intermittent Claudication"; 2000, pp. 523-530; by Excerpta Medica, Inc.	
-	19	WILLIAM R. HIATT, DILSHER NAWAZ, AND ERIC P. BRASS; "Carnitine metabolism during exercise in patients with peripheral vascular disease"; 1987; pp. 2383-2387; The American Physiological Society; Colorado School of Medicine, Denver, Co.	
-	20	THOMAS L. CLANTON AND PAUL F. KLAWITTER, "Physiological and Genomic Consequences of Intermittent Hypoxia Invited Review; Adaptive responses of skeletal muscle to intermittent hypoxia: the known and the unknown"; 2001; The American Physiological Society; pp. 2476-2487; The American Physiological Society	
-	21	M.D. BOSKA, J.A. NELSON N. SRIPATHI, I.I. PIPINOS, A.D. SHEPARD, AND K.M.A. WELCH; "P MRS Studies of Exercising Human Muscle at High Temporal Resolution"; 1999, pp. 1145-1151, Wiley-Liss, Inc.	

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	10/091,258
Filing Date	March 5, 2002
First Named Inventor	David R. Hathaway
Group Art Unit	1653
Examiner Name	.
Attorney Docket Number	P03660US7

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. †	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
---------------------	------------	---	----------------

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.